HIV Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)

2020-07-30
Price :
Published : Jul-2020
No. of Pages : 0

HIV Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)

Summary

HIV Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on HIV Tests market for the year 2020 and beyond. HIV is an ongoing, global public health issue that remains a major priority for most governments. HIV tests are performed for two purposes: i) screening and diagnosis; or ii) monitoring of HIV-positive patients, particularly those undergoing antiretroviral therapy (ART).

Screening of pregnant women for HIV is standard of care in most countries and considered to be a cost-effective strategy for reducing the risk of transmission to the baby. Women are typically screened during their first trimester of pregnancy. For pregnant women at high-risk of acquiring HIV, testing is sometimes repeated at the beginning of the third trimester (28 weeks) or at the time of delivery. The HIV diagnostic tests include POC, NAAT, Multi-parameter NAAT and EIA tests. The HIV monitoring tests include NAAT for Viral Load and CD4 Count Tests.

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are –

Currently marketed HIV Tests and evolving competitive landscape –
– Insightful review of the key industry trends.
– Annualized total HIV Tests market revenue by segment and market outlooks from 2015-2030.
– Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights –
– Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
– SWOT analysis for HIV Tests market.
– Competitive dynamics insights and trends provided for HIV Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
– Country specific overview of the healthcare system.
– Country specific reimbursement policies.
– Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories , F. Hoffmann-La Roche Ltd , Siemens Healthineers AG , Bio-Rad Laboratories Inc , Becton Dickinson and Co , OraSure Technologies Inc and Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for –
– CMO executives who must have deep understanding of the HIV Tests market place to make strategic planning and investment decisions.
– Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
– Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to –
– Understand the impact of COVID-19 on HIV Tests market.
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving HIV Tests market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HIV Tests market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track device sales in the global and country-specific HIV Tests market from 2015-2030.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2029

Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2029 Summary Meningococcal disease is an infection caused by Neisseria meningitidis bacteria, and, although relatively rare, is widely feared because of its high mortality rate even in otherwise healthy individuals. Serogroups A, B, C, W, and Y are the most common meningococcal types in the nine major markets (9MM) covered in this report (US, France, Germany, Italy, Spain, UK, Argentina, Brazil, and China), and immunization of high-risk groups such as infants and adolescents provides the best protection against the infection. Immunization with conjugated meningococcal serogroup C (MenC) is routinely recommended for infants in the 5EU and Brazil, and immunization against serogroup ACWY (MenACWY vaccines) is recommended i......
$10995

Invasive Meningococcal Disease – Epidemiology Forecast to 2029

Invasive Meningococcal Disease - Epidemiology Forecast to 2029 Summary Invasive meningococcal disease (IMD) is a life-threatening condition caused by the bacterium Neisseria meningitidis (N. meningitidis). N. meningitidis is an encapsulated gram-negative bacterium that exists without complication in roughly 5-11% of adults and up to 25% of adolescents. However, if the bacterium moves beyond the nasopharynx and invades body tissue, serious illness can arise, usually in the form of meningitis or septicemia. Symptoms of disease can include fever, headache, stiff neck, nausea, photophobia, and fatigue, among others. The bacterium is spread by respiratory droplets through close or prolonged contact with an infected person and is not as contagious as the common cold or flu. In 2019, there wer......
$3995

Ulcerative Colitis – Epidemiology Forecast to 2029

Ulcerative Colitis - Epidemiology Forecast to 2029 Summary Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the large intestine and the rectum. The inflammation occurs only in the innermost layer of the lining of the intestine. In UC, ulcers develop on the surface of the bowel lining; these may bleed and produce mucus. If the inflammation is confined to rectum, it is called proctitis (Crohn's and Colitis Foundation of America, 2014; Crohn's and Colitis UK, 2019). UC can occur at any age, though most people are diagnosed in their mid-thirties. Men and women are equally likely to be affected, but older men are more likely to be diagnosed than older women. GlobalData epidemiologists utilized historical data obtained from peer-reviewed......
$3995

Contract Dose Manufacturing Industry by the Numbers – Composition, Size, Market Share and Outlook – 2020 Edition

Contract Dose Manufacturing Industry by the Numbers - Composition, Size, Market Share and Outlook - 2020 Edition Summary This expert trend report is a comprehensive look at the finished dose contract manufacturing landscape in 2020, including analysis of dose CMO M&A activity, market size and share. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management. This report gives an important expert quantitative analysis on the contract dose manufacturing industry. Findings are based on the industry's most comprehensive database of the dose CMO industry (GlobalData's Pharma Intelligence Center Contract Service Providers Database) this analysis is driven by a ......
$4995

Egypt Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Egypt Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report, "Egypt Healthcare, Regulatory and Reimbursement Landscape - CountryFocus". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Egypt. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalDa......
$1995

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective Summary Telemedicine is the use of electronic communication for the delivery of remote clinical care. It has been recognized as a critical strategy during the ongoing coronavirus disease 2019 (COVID-19) pandemic to limit the risk of person-to-person transmission of the virus as social distancing has become the norm. It is widely anticipated that COVID-19 may be the tipping point for telemedicine as the full potential of the technology is increasingly realized by patients, healthcare systems, and payers. As a result of the pandemic, regulations and policies governing reimbursement and use of telemedicine have changed significantly, leading to expanded access and an unprecedented demand for these services.......
$1495

Greece Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Greece Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report: "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Greece". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Greece. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by Glob......
$1995

Mania Disease – Global Clinical Trials Review, H2, 2020

Mania Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Mania Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Mania Clinical trials scenario. This report provides top line data relating to the clinical trials on Mania. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are colla......
$2500

Duchenne Muscular Dystrophy Disease – Global Clinical Trials Review, H2, 2020

Duchenne Muscular Dystrophy Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Duchenne Muscular Dystrophy Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Critical Limb Ischemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Critical Limb Ischemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's propr......
$2500

Gestational Diabetes Disease – Global Clinical Trials Review, H2, 2020

Gestational Diabetes Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Gestational Diabetes Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Gestational Diabetes Clinical trials scenario. This report provides top line data relating to the clinical trials on Gestational Diabetes. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy